Neurodevelopmental Profile of Children With MARS1-Related Pulmonary Alveolar Proteinosis: A Cohort Study
Catherine Grosmaitre1,2, Mathis Le Bellego1, Nathalie Boddaert3,4
1Child Psychiatry Department, Necker Enfants Malades Hospital, Paris, France.
Insights
Children with MARS1-related pulmonary alveolar proteinosis (PAP) show significant intellectual and adaptive functioning impairments. Early monitoring and multidisciplinary interventions are crucial for optimizing outcomes in these pediatric patients.
Area of Science:
- Pediatric Neurology
- Rare Genetic Disorders
- Neurodevelopmental Pediatrics
Background:
- Pulmonary alveolar proteinosis (PAP) is a rare lung disorder caused by surfactant accumulation.
- MARS1 mutations lead to early-onset PAP with multi-organ involvement, often treated with methionine.
- The neurodevelopmental impact of MARS1-related PAP in children is not well understood.
Purpose of the Study:
- To characterize the neurodevelopmental profile of pediatric patients with MARS1-related PAP.
- To assess intellectual functioning and adaptive behavior using standardized measures.
- To inform comprehensive care strategies for affected children.
Main Methods:
- Observational cohort study of 16 pediatric patients with MARS1-related PAP (age 14 months to 7.3 years).
- Intellectual functioning assessed with Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV).
- Adaptive behavior evaluated using Vineland Adaptive Behavior Scales, Second Edition (VABS-II) via parent interviews.
Main Results:
- Mean Full-Scale IQ was 72.25 (SD=16.85), indicating borderline to mild intellectual disability.
- Average VABS-II composite scores were 69.75 (SD=23.58), showing deficits in communication, daily living, socialization, and motor skills.
- Neurodevelopmental impairments were consistent across the cohort despite methionine treatment.
Conclusions:
- Children with MARS1-related PAP exhibit significant intellectual and adaptive functioning deficits.
- A consistent neurodevelopmental profile is associated with MARS1-related PAP, even with methionine supplementation.
- Routine cognitive and developmental monitoring, alongside multidisciplinary interventions, is essential for pediatric PAP patients.
Abstract:
ImportancePulmonary alveolar proteinosis (PAP) is a rare pulmonary disorder characterized by alveolar surfactant accumulation leading to respiratory impairment. MARS1 mutations lead to an early onset PAP associated in a setting of multi-organ involvement and respond to high-dose methionine supplementation. While pulmonary manifestations of MARS1-related PAP and their response to methionine are well documented, its potential impact on cognitive and adaptive functioning in pediatric patients remains poorly understood. Understanding the neurodevelopmental profile of children with MARS1-related PAP is essential for optimizing comprehensive care and long-term outcomes. ObjectiveTo characterize the neurodevelopmental profile of children with MARS1-related PAP by assessing intellectual functioning and adaptive behavior using standardized neuropsychological measures and parent-reported questionnaires. DesignObservational cohort study including 16 pediatric patients with MARS1-related PAP aged 14 months to 7.3 years, followed at the Necker-Enfants Malades Hospital (Paris, France) and treated with methionine. Intellectual functioning was assessed using the Wechsler Preschool and Primary Scale of Intelligence, Fourth Edition (WPPSI-IV) when age-appropriate, and adaptive behavior was evaluated via the Vineland Adaptive Behavior Scales, Second Edition (VABS-II) through parent interviews. ResultsSixteen children with MARS1-related PAP underwent the full evaluation. Methionine was started at a median age of 6 months (IQR [5, 15]). Eight of them were able to undergo the WPPSI-IV assessment. The mean Full-Scale IQ was 72.25 (SD = 16.85), indicating borderline to mild intellectual disability relative to normative data. Adaptive behavior composite scores on the VABS-II averaged 69.75 (SD = 23.58), reflecting significant deficits across communication, daily living skills, socialization, and motor domains. The neurodevelopmental impairments were relatively homogeneous across the cohort. ConclusionsChildren with MARS1-related pulmonary alveolar proteinosis exhibit marked impairments in intellectual and adaptive functioning, suggesting a consistent neurodevelopmental profile associated with the disease, and despite methionine supplementation. These findings highlight the need for routine cognitive and developmental monitoring in pediatric PAP patients and support the development of multidisciplinary interventions addressing both respiratory and neurodevelopmental outcomes.
Related Concept Videos
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...
Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Respiratory Syncytial Virus Disease
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
Chronic Inflammation
